Aardvark Therapeutics (AARD) IPO deck
Aardvark Therapeutics is a clinical-stage biopharmaceutical company developing novel small-molecule therapeutics targeting Bitter Taste Receptors (TAS2Rs) to treat metabolic diseases, with its lead candidate, ARD-101, in Phase 3 trials for hyperphagia associated with Prader-Willi Syndrome.
%20IPO%20deck){kind=link}